scholarly journals Structural and functional brain alterations associated with cancer‐associated cognitive decline in gastric cancer patients: A preliminary longitudinal neuroimaging study

2021 ◽  
Author(s):  
Jaeun Ahn ◽  
DeokJong Lee ◽  
Young‐Chul Jung ◽  
Kyung Ran Kim
Keyword(s):  
Gastric Cancer ◽  
Cognitive Decline ◽  
Cancer Patients ◽  
Functional Brain ◽  
Neuroimaging Study ◽  
Gastric Cancer Patients

scholarly journals Structural and Functional Brain Alterations in Post-Chemotherapy Cognitive Impairment in Gastric Cancer: A Longitudinal Multimodal Neuroimaging Study

2020 ◽  
Author(s):  
Jaeun Ahn ◽  
DeokJong Lee ◽  
Young-Chul Jung ◽  
KYUNG RAN KIM
Keyword(s):  
Gastric Cancer ◽  
Cognitive Impairment ◽  
Adjuvant Chemotherapy ◽  
Cancer Patients ◽  
Resting State ◽  
Self Report ◽  
Significant Group ◽  
Left Hippocampus ◽  
Neuroimaging Study ◽  
Gastric Cancer Patients

Abstract Backgrounds: Despite clinical significance of chemobrain, no longitudinal study has been made on change in cognitive function related to chemotherapy in gastric cancer. The aim of this study is to define structural and functional changes in brains of gastric cancer patients caused by chemotherapy-induced cognitive impairment after adjuvant chemotherapy. Methods: 13 gastric cancer patients with adjuvant chemotherapy (CTx+ group), 9 gastric patients without adjuvant chemotherapy (CTx- group), and 10 healthy controls (HC) were enrolled for this study. We performed self-report questionnaires, neurocognitive tests, voxel-based morphometry (VBM), hippocampus-seeded resting-state functional magnetic resonance imaging (rsfMRI) and diffusion tensor imaging (DTI) analysis twice at before and 3 months after chemotherapy. Results: Compared to CTx- group, CTx+ group exhibited statistically significant decrease in attention and executive function over time, and also exhibited dysfunction in delayed recognition performance. Results in resting state functional connectivity analysis show significant group-by-time interaction in left hippocampus-anterior thalamus. In addition, DTI analysis had interesting results that showed reduced fractional anisotropy (FA), and increased mean diffusivity (MD) in left hippocampus. However, results from VBM analysis confirms that chemotherapy does not cause structural changes in brain. Conclusion: To the best of our knowledge, this is the first longitudinal neuroimaging study on the effect of chemotherapy in gastric cancer patients. Based on the results of this study, we suggest that neuropathological processes and clinical presentation of chemobrain is ultimately similar disease as age-related neurodegenerative disorder. Results of this study help in viewing underlying basis of chemobrain at a new angle and puts emphasis in importance of continuous assessment and intervention.

CLINICAL SIGNIFICANCE OF SERUM CAVEOLIN-1 LEVELS IN GASTRIC CANCER PATIENTS

2018 ◽  
Vol 40 (4) ◽  
pp. 323-327 ◽  
Author(s):  
F Tas ◽  
S Karabulut ◽  
K Erturk ◽  
D Duranyildiz
Keyword(s):  
Gastric Cancer ◽  
Cancer Patients ◽  
Histological Grade ◽  
Clinical Importance ◽  
Disease Stage ◽  
Control Group ◽  
Tissue Samples ◽  
Caveolin 1 ◽  
Study Results ◽  
Gastric Cancer Patients

Aim: Caveolin-1 plays a significant role in the pathogenesis of various carcinomas and its expression affects the survival of cancer patients. However, the molecular function of caveolin-1 and its possible clinical importance has remained uncertain in gastric cancer. No clinical trial has examined serum caveolin-1 levels in gastric cancer patients so far, instead all available results were provided from studies conducted on tissue samples. In the current study, we analyzed the soluble serum caveolin-1 levels in gastric cancer patients, and specified its associations with the clinical factors and prognosis. Material and Methods: Sixty-three patients with pathologically confirmed gastric cancer were enrolled into the trial. Serum caveolin-1 concentrations were detected by ELISA method. Thirty healthy subjects were also included in the study. Results: The median age of patients was 62 years, ranging from 28 to 82 years. The serum caveolin-1 levels in gastric cancer patients were significantly higher than those in control group (p < 0.001). The common clinical parameters including patient age, sex, lesion localization, histopathology, histological grade, disease stage, and various serum tumor markers (e.g. LDH, CEA, and CA 19.9) were not found to be associated with serum caveolin-1 levels (p > 0.05). Similarly, no correlation existed between serum caveolin-1 concentration and chemotherapy responsiveness (p = 0.93). Furthermore, serum caveolin-1 level was not found to have a prognostic role (p = 0.16). Conclusion: Even though it is neither predictive nor prognostic, serum caveolin-1 level may be a valuable diagnostic indicator in patients with gastric cancer. Key

DETERMINATION OF P53 GENE CODON 72 POLYMORPHISMS IN PATIENTS WITH GASTRIC CANCER

2013 ◽  
pp. 11-17
Author(s):  
Thi Tuy Ha Nguyen ◽  
Thi Minh Thi Ha
Keyword(s):  
Gastric Cancer ◽  
Cancer Patients ◽  
P53 Gene ◽  
Diffuse Gastric Cancer ◽  
Codon 72 ◽  
Cancer Group ◽  
Pcr Rflp ◽  
Gastric Cancer Patients ◽  
The Relationship

Background: The role of p53 gene in the gastric cancer is still controversial. This study is aimed at determining the rate of the p53 gene codon 72 polymorphisms in gastric cancer patients and evaluating the relationship between these polymorphisms and endoscopic and histopathological features of gastric cancer. Patients and methods: Sixty eight patients with gastric cancer (cases) and one hundred and thirty six patients without gastric cancer (controls) were enrolled. p53 gene codon 72 polymorphisms were determined by PCR-RFLP technique with DNA extracted from samples of gastric tissue. Results: In the group of gastric cancer, Arginine/Argnine, Arginine/Proline and Proline/Proline genotypes were found in 29.4%, 42.7% and 27.9%, respectively. The differences of rates were not statistically significant between cases and controls (p > 0,05). In males, the Proline/Proline genotype was found in 38.1% in patients with gastric cancer and more frequent in patients without gastric cancer (15.7%, p = 0,01). An analysis of ROC curve showed that the cut-off was the age of 52 in the Proline/Proline genotype, but it was 65 years old in the Arginine/Proline genotype. The Proline/Proline genotype was found in 41.9% in Borrmann III/IV gastric cancer, this rate was higher than Borrmann I/II gastric cancer (16.2%, p = 0.037) and also higher than controls (18.4%, p = 0,01). The rate of Proline/Proline genotype was 41.7% in the diffuse gastric cancer, it was higher than in controls (p = 0,023). Conclusion: No significative difference of rate was found in genotypes between gastric cancer group and controls. However, there was the relationship between Proline/Proline genotype and gastric cancer in males, Borrmann types of gastric cancer, the diffuse gastric cancer. Key words: polymorphism, codon 72, p53 gene, PCR - RFLP, gastric cancer.

A PILOT STUDY OF HER-2/NEU GENE AMPLIFICATION ASSESSED BY FLUORESCENCE IN SITU HYBRIDIZATION (FISH) IN GASTRIC CANCER

2014 ◽  
pp. 15-20
Author(s):  
Van Huy Tran ◽  
Thi Minh Thi Ha ◽  
Trung Nghia Van ◽  
Viet Nhan Nguyen ◽  
Phan Tuong Quynh Le ◽  
...  
Keyword(s):  
Gastric Cancer ◽  
In Situ Hybridization ◽  
Fluorescence In Situ Hybridization ◽  
Cancer Patients ◽  
Gene Amplification ◽  
Cancer Tissue ◽  
Tissue Samples ◽  
Her 2 ◽  
Gastric Cancer Patients

Background: HER-2/neu is a predictive biomarker for treatment of gastric cancer using trastuzumab in combination with chemotherapy. This study aimed to evaluate the status of HER-2/neu gene amplification using fluorescence in situ hybridization (FISH) in gastric cancer. Patients and methods: thirty six gastric cancer patients were assessed HER-2/neu gene amplification by FISH using PathVysionTM HER-2 DNA Probe kit (including HER-2/neu probe and CEP-17 probe) with biopsy and surgical specimens. Results: The HER-2/neu gene amplification was observed in three cases (8.3%), the HER-2/neu gene amplification rate in Lauren’s intestinal-type and diffuse-type were 11.8% and 5.2%, respectively. Conclusion: We applied successfully FISH technique with gastric cancer tissue samples. This technique could be performed as routine test in gastric cancer in order to select patients that benefit from trastuzumab in combination with chemotherapy.

Sign in / Sign up

Export Citation Format

Share Document